MOA LIFE PLUS CO. LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2,560 KRW | -3.03% |
|
-33.42% | +20.19% |
| Sales 2022 | 100B 73.8M 5.91B | Sales 2023 | 18.25B 13.41M 1.07B | Capitalization | 68.75B 50.53M 4.05B |
|---|---|---|---|---|---|
| Net income 2022 | -23.14B -17.01M -1.36B | Net income 2023 | 8.01B 5.89M 471M | EV / Sales 2022 | 1.32 x |
| Net Debt 2022 | 20.64B 15.17M 1.21B | Net cash position 2023 | 12.62B 9.27M 742M | EV / Sales 2023 | 3.08 x |
| P/E ratio 2022 |
-4.45
x | P/E ratio 2023 |
8.55
x | Employees | - |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 88.83% |
More Fundamentals
* Assessed data
More news
| 1 day | -3.03% | ||
| 1 week | -33.42% | ||
| Current month | -37.18% | ||
| 1 month | +0.99% | ||
| 3 months | +57.06% | ||
| 6 months | +43.82% | ||
| Current year | +20.19% |
1 week
2 500.00
4 500.00
1 month
2 500.004 500.00
Current year
1 584.004 500.00
1 year
1 500.004 500.00
3 years
1 500.0018 450.00
5 years
1 500.0018 450.00
10 years
1 500.0030 600.00
| Managers | Title | Age | Since |
|---|---|---|---|
Young-Chul Park
CEO | Chief Executive Officer | 56 | - |
Chun-Soo Lee
PSD | President | 73 | - |
Byung-Gyun Ham
AUD | Comptroller/Controller/Auditor | 56 | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Jun-Woo Park
BRD | Director/Board Member | 48 | - |
Chun-Soo Lee
PSD | President | 73 | - |
Young-Chul Park
CEO | Chief Executive Officer | 56 | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 06/05/24 | 2,560 | -3.03% | 1 091 374 |
| 03/05/24 | 2,640 | -20.00% | 3,200,716 |
| 02/05/24 | 3,300 | -19.02% | 5,016,971 |
| 30/04/24 | 4,075 | +5.98% | 519,108 |
End-of-day quote Korea S.E., May 06, 2024
More quotes
Moa Life Plus, formerly BL Corp, is a Korea-based company primarily engaged in the research and development of biotechnology and biopharmaceuticals. The Company is engaged in the manufacture and sale of health functional foods and functional cosmetics. In addition, the Company is engaged in the distribution of pharmaceuticals and medical supplies. The Company is engaged in the development of cervical cancer treatment, anticancer drugs and other products.
Sector
Pharmaceuticals
Calendar
13/05/2024
- Q1 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| +20.19% | 73.42M | |
| +33.44% | 690B | |
| +26.43% | 546B | |
| -5.16% | 358B | |
| +18.98% | 323B | |
| +4.86% | 287B | |
| +14.32% | 235B | |
| +5.79% | 199B | |
| -9.49% | 195B | |
| +3.98% | 161B |
- Stock Market
- Equities
- A142760 Stock
